Literature DB >> 2874279

Evaluation of serological cross-reactivity between antibodies to Plasmodium and HTLV-III/LAV.

A E Greenberg, C A Schable, A J Sulzer, W E Collins.   

Abstract

Serum samples from 460 patients with existing or previous Plasmodium infections, high antimalarial antibody titres, and no apparent risk of exposure to human T-lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV) were assayed for HTLV-III/LAV antibody; only 1 sample, from a 21-year-old African woman, was strongly reactive by enzyme-linked immunosorbent assay (ELISA) and positive by western blot. Conversely, no sample from 100 HTLV-III/LAV-positive American homosexual men was strongly reactive for antibodies to the four Plasmodium species that infect human beings by an indirect fluorescent antibody technique, or for antibodies to Plasmodium falciparum by an ELISA technique. Thus, exposure to Plasmodium does not result in HTLV-III/LAV seropositivity, and HTLV-III/LAV antibodies are not strongly cross-reactive with malarial antigens.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2874279     DOI: 10.1016/s0140-6736(86)92071-4

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  5 in total

1.  Specificity of routine parasite serological tests in autoimmune disorders, neoplastic disease, EBV-induced mononucleosis, and HIV infection.

Authors:  W Kern; C Kirsten; P Förster; H J Diesfeld; E Vanek
Journal:  Klin Wochenschr       Date:  1987-10-01

2.  [Malaria tropica in HIV infection].

Authors:  T Weinke; W Scherer; H D Pohle
Journal:  Klin Wochenschr       Date:  1990-05-17

3.  False-positive results of enzyme immunoassays for human immunodeficiency virus in patients with uncomplicated malaria.

Authors:  Anne F Gasasira; Grant Dorsey; Moses R Kamya; Diane Havlir; Moses Kiggundu; Philip J Rosenthal; Edwin D Charlebois
Journal:  J Clin Microbiol       Date:  2006-08       Impact factor: 5.948

Review 4.  Proposed immunopathogenic factors associated with progression from human immunodeficiency virus seropositivity to clinical disease.

Authors:  D J Mock; N J Roberts
Journal:  J Clin Microbiol       Date:  1987-10       Impact factor: 5.948

5.  Chloroquine enhances replication of Semliki Forest virus and encephalomyocarditis virus in mice.

Authors:  R K Maheshwari; V Srikantan; D Bhartiya
Journal:  J Virol       Date:  1991-02       Impact factor: 5.103

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.